<SEC-DOCUMENT>0001144204-16-074984.txt : 20160111
<SEC-HEADER>0001144204-16-074984.hdr.sgml : 20160111
<ACCEPTANCE-DATETIME>20160111083041
ACCESSION NUMBER:		0001144204-16-074984
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160111
FILED AS OF DATE:		20160111
DATE AS OF CHANGE:		20160111

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36000
		FILM NUMBER:		161335138

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v428745_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 3pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of January, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <B>000-36000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>XTL Biopharmaceuticals Ltd.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5 HaCharoshet St.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Raanana 4365603</B><BR>
<B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Israel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B>Incorporation by Reference: This Form 6-K of XTL Biopharmaceuticals
Ltd. is hereby incorporated by reference into the registration statements on Form S-8 (File No. 333-148085, File No. 333-148754
and File No. 333-154795) and Form F-3 (File No. 333-194338).</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 3pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tlogo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>XTL
Biopharmaceuticals SUBMITS PROTOCOL TO YEDA FOR ADVANCED CLINICAL TRIAL OF hCDR1 IN THE TREATMENT OF LUPUS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>hCDR1 addresses significant unmet
medical need for lupus, a chronic and complex disease for which there is currently no cure</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>RAANANA,
Israel</B></FONT><B> - (January 11, 2016) &ndash; <FONT STYLE="color: #0000FF"><U>XTL Biopharmaceuticals Ltd.</U></FONT> (NASDAQ:
XTLB, TASE: XTL) </B>(&ldquo;XTL&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage biopharmaceutical company developing its
lead product for the treatment of lupus, today announced that it has submitted the full protocol for its advanced stage clinical
trial of hCDR1 for the treatment of systemic lupus erythematosus (SLE) to Yeda Research and Development Company Ltd. (Yeda).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL previously announced that it has submitted
a Pre-IND meeting package to the US Food and Drug Administration and expects to receive written responses regarding its proposed
clinical study in the coming weeks. A Phase 2b clinical trial of hCDR1 was previously completed and the compound has shown a favorable
safety profile in over 400 patients and efficacy in at least one clinically relevant endpoint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Submission of this clinical trial protocol
marks a milestone for XTL in its development of hCDR1, which the Company is developing under license from Yeda, the technology
transfer arm of the world-renowned Weizmann Institute of Science.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Josh Levine, Chief Executive Officer of
XTL, commented, &ldquo;We are pleased to have met this important milestone and to continue our partnership with Yeda in the development
of this novel drug for the benefit of lupus patients. We are making good progress in all of our regulatory, clinical and chemistry,
manufacturing and control (CMC) activities and expect to meet the remaining development milestones.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amir Naiberg, Chief Executive Officer of
Yeda added, &ldquo;We are encouraged by the progress that XTL has made to date with hCDR1 and we look forward to XTL&rsquo;s continued
development of the drug for the treatment of SLE.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About hCDR1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">hCDR1 is a novel compound with a unique
mechanism of action and with clinical data on over 400 patients in 3 clinical studies. The drug has a favorable safety profile,
is well tolerated by patients and has demonstrated efficacy in at least one clinically meaningful endpoint. For more information
please see a peer reviewed article in Lupus Science and Medicine journal (<FONT STYLE="color: #0000FF"><U>http://lupus.bmj.com/content/2/1/e000104.full</U></FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</td>
    <TD STYLE="text-align: center; width: 60%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XTL Biopharmaceuticals Ltd.</font></td>
    <TD STYLE="width: 20%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 Hacharoshet Street, Raanana, 43656, Israel</font></td>
    <TD STYLE="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 1</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +972 9 955 7080;
    email: <FONT STYLE="color: #0000FF"><U>ir@xtlbio.com</U></FONT></FONT></td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tlogo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About Systemic Lupus Erythematosus (SLE)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lupus is a chronic autoimmune disease involving many systems
in the human body, including joints, kidneys, central nervous system, heart, hematological system and others. The biologic basis
of the disease is a defect in the immune (defense) system, leading to production of self (auto) antibodies, attacking the normal
organs and causing irreversible damage. According to the Lupus Foundation of America, at least 1.5 million Americans have the disease
(more than 5 million worldwide) with more than 16,000 new cases diagnosed each year. The majority of patients are women of childbearing
years. There has been only one drug approved by the FDA in the last over 50 years and recently two of the few drugs in advanced
development did not meet their primary endpoints in Phase 3 trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About Yeda Research and Development Company</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yeda Research and Development Company Ltd. is the commercial
arm of the Weizmann Institute of Science, one of the world&rsquo;s leading multidisciplinary research institutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About XTL Biopharmaceuticals Ltd.
(XTL)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL Biopharmaceuticals Ltd., a biopharmaceutical
company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of unmet clinical
needs with a focus on treatments for autoimmune diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL is a public company, traded on the
Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL shares are included in the following indices:
Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>For further information, please contact:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Relations, XTL Biopharmaceuticals
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: <FONT STYLE="color: #0000FF"><U>ir@xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #0000FF"><U>www.xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</td>
    <TD STYLE="text-align: center; width: 60%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XTL Biopharmaceuticals Ltd.</font></td>
    <TD STYLE="width: 20%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 Hacharoshet Street, Raanana, 43656, Israel</font></td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: right; margin-bottom: 0pt">Page 2</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +972 9 955 7080;
    email: <FONT STYLE="color: #0000FF"><U>ir@xtlbio.com</U></FONT></FONT></td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tlogo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Cautionary Statement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain forward-looking
statements, about XTL&rsquo;s expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as &quot;believe,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;may,&quot;
&quot;should&quot; or &quot;anticipate&quot; or their negatives or other variations of these words or other comparable words or
by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases
or oral statements made by or with the approval of one of XTL&rsquo;s authorized executive officers. Forward-looking statements
relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause
XTL&rsquo;s actual results to differ materially from any future results expressed or implied by the forward-looking statements.
Many factors could cause XTL&rsquo;s actual activities or results to differ materially from the activities and results anticipated
in such forward-looking statements, including, but not limited to, the factors summarized in XTL&rsquo;s filings with the SEC and
in its periodic filings with the TASE. In addition, XTL operates in an industry sector where securities values are highly volatile
and may be influenced by economic and other factors beyond its control. XTL does not undertake any obligation to publicly update
these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors
associated with an investment in our ADSs or ordinary shares which are included in our Annual Report on Form 20-F as filed with
the U.S. Securities and Exchange Commission on April 28 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</td>
    <TD STYLE="text-align: center; width: 60%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XTL Biopharmaceuticals Ltd.</font></td>
    <TD STYLE="width: 20%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 Hacharoshet Street, Raanana, 43656, Israel</font></td>
    <TD STYLE="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 3</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +972 9 955 7080;
    email: <FONT STYLE="color: #0000FF"><U>ir@xtlbio.com</U></FONT></FONT></td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>XTL BIOPHARMACEUTICALS LTD.</B></FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</td>
    <TD STYLE="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 50%"><font style="font-family: Times New Roman, Times, Serif">Date: January 11, 2016</font></td>
    <TD STYLE="width: 20%">&nbsp;</td>
    <TD STYLE="text-align: center; width: 3%"><font style="font-family: Times New Roman, Times, Serif">By:</font></td>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 27%; padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif">/s/ Josh Levine</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: left; padding-left: 0.25in"><font style="font-family: Times New Roman, Times, Serif">Josh Levine</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD COLSPAN="2" STYLE="text-align: left"><font style="font-family: Times New Roman, Times, Serif">Chief Executive Officer</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 00$" P$1  (1 0,1 ?_$ .$    & P$! 0
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M3RBI2ES*A,J5WB=.V)CL7N';]T-MZ++;70MVVA>FE-.A*4H;"0DR2E'= [W
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M%!:P 2.8D:&VBZR<GMER9LVY/)6V1Q81](2D)>9GH%+X^*.8]XJ4"E))$^4
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M"J;>9R>%(HE5E1,QF KD?&8SS\<,[ZQ;=2W'8]Z\.C_<TU12*;/D\9YI"_\
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MZTP'V8$B*\X\H4A]\A;+=3IX;4DMJ4EPM)2OER4"6A[.;LVO=''DU*2EJ_,
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MHK\,(:<6F7ODK4A2P1H4:@D:PM_N!6@Y8NUC1>TE\I%MRK:H84@9((I=#>B
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M=0IQ;2LC);B.H"0"2D$$^.-S]:^4TEIVR8Q(*3])N52W),^\$4RVW 2.P&1
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M?*$1S9 $;DVZ?^(?DF+*:C?!L7W-/F&%,PQ6#4W[4D^XK_DG!!%=CWXR!O\
M;R!(!]X*3P)_@##1>E7U5M?I"_N1@7J$!.?.2_P4?=AF5M];*PXR\MEQ/M7&
MG%-K3]):%)4/V<:24@*'*H33YQ.*+25I/,F8,'/?>J#PJM1^,)7]=CU_1F/\
M-'Q1[D>SQG_OE?;@>_%4_P"K5'XPE?UV#Z,S_AH^*/<@\9_[Y7VX'OQ5/^K5
M'XPE?UV#Z,S_ (:/BCW(/&?^^5]N/E=8JG(O^UJC[57_ ,A*]0_^-@%.Q/\
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M<<D(;)(2EP\Z0L<,Z=4G4C2Y,R[MU@KO/9^>574IF/&*>++<Y'D"M5* ',I
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MJQ[UUT?2'D^=#SW.X@^=*AII#D=HV13+7AMLQF4!03DI03[(Y9^4C/B<5B
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09YOVB?I8((^\$$#!!'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
